Get the Stockscreener App
19.79
3.94%
0.75
After Hours:
19.90
0.11
+0.56%
Legend Biotech Corp Adr stock is traded at $19.79, with a volume of 1.41M.
It is up +3.94% in the last 24 hours and up +12.00% over the past month.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
See More
Previous Close:
$19.04
Open:
$19.25
24h Volume:
1.41M
Relative Volume:
0.65
Market Cap:
$3.85B
Revenue:
$1.14B
Net Income/Loss:
$-250.98M
P/E Ratio:
-14.55
EPS:
-1.36
Net Cash Flow:
$-251.61M
1W Performance:
+5.77%
1M Performance:
+12.00%
6M Performance:
-3.56%
1Y Performance:
-41.31%
1-Day Range:
$18.85
$19.92
1-Week Range:
$17.56
$19.92
52-Week Range:
$16.24
$37.50
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Name
Legend Biotech Corp Adr
Sector
Industry
Phone
-
Address
-
Compare LEGN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
19.79 | 3.85B | 1.14B | -250.98M | -251.61M | -1.36 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-26 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-24-26 | Downgrade | UBS | Buy → Neutral |
| Jul-13-26 | Resumed | JP Morgan | Neutral |
| Feb-12-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jan-22-26 | Downgrade | TD Cowen | Buy → Hold |
| Jan-07-26 | Initiated | Oppenheimer | Outperform |
| Oct-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Jun-17-24 | Initiated | Truist | Buy |
| May-24-24 | Reiterated | H.C. Wainwright | Buy |
| May-23-24 | Initiated | Deutsche Bank | Buy |
| Apr-17-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Apr-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | Raymond James | Outperform |
| Dec-19-23 | Initiated | Scotiabank | Sector Perform |
| Nov-06-23 | Initiated | Goldman | Buy |
| May-25-23 | Initiated | William Blair | Mkt Perform |
| May-22-23 | Initiated | Daiwa Securities | Buy |
| Mar-29-23 | Initiated | H.C. Wainwright | Buy |
| Mar-24-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-22 | Initiated | UBS | Buy |
| Nov-02-22 | Initiated | Evercore ISI | Outperform |
| Nov-01-22 | Initiated | Cowen | Outperform |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Mar-15-22 | Initiated | Barclays | Overweight |
| Jan-31-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-21-21 | Initiated | Piper Sandler | Overweight |
| May-18-21 | Initiated | BTIG Research | Buy |
| Jul-01-20 | Initiated | JP Morgan | Overweight |
| Jul-01-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Morgan Stanley | Overweight |
View All
Legend Biotech Corp Adr Stock (LEGN) Latest News
Learn Why The Bull Case For Legend Biotech Stock Could Change Following Five Year CARVYKTI Data - Simply Wall Street
Legend Biotech Director Corazon Sanders Sells 27,370 Shares at $9.46 Average Price - Kalkine Media
Legend Biotech Corporation (LEGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Legend Biotech (NasdaqGS:LEGN) Stock Forecast & Analyst Predictions - Simply Wall Street
Can Legend Biotech (LEGN) Turn Cell Therapy Scale Into Compounding Wealth? - Yahoo Finance
Data on five-year remission with a myeloma treatment will be presented in Scotland - Stock Titan
Legend Biotech (LEGN) Falls 3.5% to $19.78, Pressing Down on Key Support as CAR-T Sector WeakensVolume Breakout Ideas - https://www.dars.gov.et/
Legend Biotech (LEGN) Falls 3.5% to $19.78, Pressing Down on Key Support as CAR-T Sector WeakensElliott Wave Entry - dars.gov.et
Stevanato Group S.p.A. (STVN) Stock Price & News - Syfe
H.C. Wainwright reiterates Legend Biotech stock rating at buy - investing.com
Legend Biotech (LEGN) Institutional Ownership 2026 - MarketBeat
Legend Biotech (LEGN) Declines 2.9% as Shares Approach Key $19.65 SupportPassive Flow - siam.in
Legend (LEGN) Q2 2026 Results: The Available Earnings Metric Delivers a Beat on the Day; After Earnings: Shares Move Lower 4.03% in Latest TradingDebt Analysis Report - https://www.dars.gov.et/
Legend (LEGN) Quarterly Results: EPS Clears the Reported Estimate at the Close; Latest Reaction: Shares Rise 3.10% for the Current SessionRevenue Warning Signal - dars.gov.et
Legend (LEGN) Quarterly Results: EPS Clears the Reported Estimate at the Close; Latest Reaction: Shares Rise 3.10% for the Current SessionEarnings Momentum Score - dars.gov.et
Legend (LEGN) Quarterly Results: EPS Clears the Reported Estimate at the Close; Latest Reaction: Shares Rise 3.10% for the Current SessionEPS Surprise History - dars.gov.et
Legend (LEGN) Quarterly Results: EPS Clears the Reported Estimate at the Close; Latest Reaction: Shares Rise 3.10% for the Current SessionEarnings Beat Alert - www.dars.gov.et
Legend Biotech (NASDAQ: LEGN) targets 19.1M new stock awards - Stock Titan
Legend (LEGN) Quarterly Update: EPS Exceeds Its Estimate in Latest Trading; Shares After the Report - dars.gov.et
Legend Biotech (NASDAQ:LEGN) Trading Down 5.3% Following Analyst Downgrade - MarketBeat
Oppenheimer downgrades Legend Biotech stock rating on M&A concerns - Investing.com
Oppenheimer downgrades Legend Biotech stock rating on M&A concerns By Investing.com - Investing.com South Africa
Oppenheimer downgrades Legend Biotech stock rating on M&A concerns By Investing.com - Investing.com India
Why is Legend Biotech stock sliding today? - Investing.com
Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript - theglobeandmail.com
Legend Biotech (NASDAQ:LEGN) Shares Gap Up After Strong Earnings - MarketBeat
Why is Legend Biotech stock surging today? By Investing.com - Investing.com South Africa
Legend Biotech Q2 2026 slides: first profitable quarter, 50% growth - Investing.com
Legend Biotech Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Legend Biotech tops Q2 2026 estimates as stock rises 5% - Investing.com
Why is Legend Biotech stock surging today? - Investing.com
Legend Biotech stock rises 5% on earnings and revenue beat By Investing.com - Investing.com South Africa
Legend Biotech stock rises 5% on earnings and revenue beat By Investing.com - Investing.com India
Legend Biotech stock rises 5% on earnings and revenue beat - Investing.com
Legend Biotech (NASDAQ:LEGN): What Could Today’s Update Reveal About Cell-Therapy Demand And Manufacturing? - Kalkine Media
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights - Yahoo Finance
Legend Biotech in spotlight: Earnings test Carvykti momentum - Investing.com
1,915,056 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Purchased by Assenagon Asset Management S.A. - MarketBeat
LEGN Q1 2026 Earnings: Wider-Than-Expected Loss, Yet Shares Rally 7.6%Retail Earnings Report - careplusvn.com
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sei Investments Co. Buys 221,899 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - marketbeat.com
Renaissance Technologies LLC Purchases 119,000 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Arrowstreet Capital Limited Partnership Acquires 315,176 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - marketbeat.com
H.C. Wainwright reiterates Buy on Legend Biotech stock at $65 - Investing.com
H.C. Wainwright reiterates Buy on Legend Biotech stock, $65 target - Investing.com
Raymond James cuts Legend Biotech stock price target on CEO departure - Investing.com
Why is Legend Biotech stock sliding today? By Investing.com - Investing.com South Africa
Why is Legend Biotech stock sliding today? - Investing.com
Legend Biotech stock falls as CEO Ying Huang steps down By Investing.com - Investing.com South Africa
Legend Biotech stock falls as CEO Ying Huang steps down - Investing.com
Legend Biotech Corp Adr Stock (LEGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Legend Biotech Corp Adr Stock (LEGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sanders Corazon (Corsee) D. | Director |
Sep 29 '26 |
Proposed Sale |
18.92 |
13,685 |
258,915 |
0 |
| Santos Carlos E | Officer |
Sep 22 '26 |
Proposed Sale |
18.73 |
2,715 |
50,854 |
0 |
| Huang Ying | Former Officer & Director |
Sep 22 '26 |
Proposed Sale |
18.65 |
69,812 |
1,302,109 |
0 |
| Santos Carlos E | Chief Financial Officer |
Sep 21 '26 |
Sale |
9.14 |
5,430 |
49,630 |
14,246 |
| Casey Patrick John | Director |
Jun 30 '26 |
Proposed Sale |
29.60 |
3,000 |
88,800 |
0 |
| Huang Ying | Officer |
Jun 26 '26 |
Proposed Sale |
28.39 |
2,783 |
79,017 |
0 |
| Huang Ying | Chief Executive Officer |
Jun 25 '26 |
Sale |
14.78 |
5,566 |
82,265 |
241,872 |
| Yeung Jessie | Officer |
Mar 26 '26 |
Proposed Sale |
17.54 |
1,862 |
32,663 |
0 |
| Huang Ying | Officer |
Mar 26 '26 |
Proposed Sale |
17.54 |
4,968 |
87,149 |
0 |
| Huang Ying | Chief Executive Officer |
Mar 25 '26 |
Sale |
8.77 |
9,936 |
87,139 |
247,438 |
2.32%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):